Fig. 4

ROC Plotter showing correlations between ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, ERCC6, and ERCC8 gene expression levels and endocrine therapy sensitivity using (A). pathological complete response (PCR) and (B). relapse-free survival (RFS) approaches. ROC Plotter showing correlations between ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, ERCC6, and ERCC8 gene expression levels and anti-HER2 therapy sensitivity using (C). PCR and (D). RFS approaches. ROC Plotter showing correlations between ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, ERCC6, and ERCC8 gene expression levels and chemotherapy sensitivity using (E). PCR and (F). RFS approaches